Neumora plans clinical trials, data readouts through 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Big Stock Moves on NLRP3 Competitive Landscape News; Positive Read-throughs for Neumora Therapeutics (NMRA) - Mizuho
January 7, 2026 1:20 PM ESTMizuho analyst Graig Suvannavejh reiterated an Outperform rating and $6.00 price target on Neumora Therapeutics (NASDAQ: NMRA)
The analyst comets "NMRA shares are +25-30 intraday (vs. +3% XBI) and +50% (vs. +5% XBI) over the past two trading sessions, following we believe recent media... More
